

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)*

**ANNOUNCEMENT
PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD
FOR THE SIX MONTHS ENDED 30 JUNE 2025**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 14 August 2025 (the “**Announcement**”) in relation to the preliminary financial data for the six months ended 30 June 2025 (the “**Reporting Period**”) of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data and indicators of Sinopharm Accord for the Reporting Period as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

PRINCIPAL UNAUDITED FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD

Unit: Ten Thousand Yuan

Currency: RMB

	The Reporting Period	Same period of last year	Increase/Decrease (%)
Total revenue	3,679,659.84	3,778,598.06	-2.62
Operating profit	92,649.65	94,886.01	-2.36
Total profit	91,811.33	95,796.89	-4.16
Net profit attributable to shareholders of the listed company	66,590.73	74,348.72	-10.43
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	64,286.16	71,137.85	-9.63
Basic earnings per share (Yuan)	1.20	1.34	-10.45
Weighted average return on net assets	3.70%	4.19%	Decreased by 0.49 percentage point

	At the end of the Reporting Period	At the beginning of the Reporting Period	Increase/Decrease (%)
Total assets	5,042,613.58	4,755,586.04	6.04
Equity attributable to shareholders of listed company	1,813,617.18	1,766,952.84	2.64
Share capital (in 0'000 shares)	55,656.51	55,656.51	0.00
Net assets per share attributable to shareholders of listed company (Yuan)	32.59	31.75	2.65

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

In the first half of 2025, Sinopharm Accord achieved a revenue of RMB36.797 billion, representing a year-on-year decrease of 2.62%; a net profit attributable to shareholder of the listed company of RMB666 million, representing a year-on-year decrease of 10.43%. Accordingly, the basic earnings per share decreased by 10.45% year-on-year and the weighted average return on net assets decreased by 0.49 percentage point year-on-year. The details of each segment are as follows:

During the Reporting Period, the distribution segment has achieved a revenue of RMB26.783 billion, representing a year-on-year decrease of 1.09%; a net profit of RMB482 million, representing a year-on-year decrease of 7.82%. The sales revenue from the distribution segment slightly declined, which was mainly due to the impact of factors such as changes in industry policy and intensified market competition. Due to delays in downstream payments, there has been an increase in aged account receivables. As a result, the provision for bad debts has risen year-on-year, contributing to a decline in profits. The retail segment (i.e., Sinopharm Holding Guoda Drugstore Co., Ltd., “**Guoda Drugstore**”) has achieved a revenue of RMB10.479 billion, representing a year-on-year decrease of 6.46%, and a net profit of RMB17 million, representing a year-on-year increase of 215.81%. The sales revenue of Guoda Drugstore declined year-on-year, which was due to the combined impact of factors such as the market environment, competition landscape and strategic store closure. In the meantime, Guoda Drugstore continuously optimized the commercial procurement system and business structure, enhanced its profitability by accelerating the building of self-owned brands and increasing the proportion of centralized procurement and other measures, focused on the enhancement of front-end operation quality of stores, strategic store closure and the enhancement of operation quality of each store, reducing related expenses such as labor costs and store rents, resulting in a year-on-year increase of the net profit of Guoda Drugstore during the Reporting Period.

Besides, affected by factors such as pharmaceutical industry policies and market supply and demand, the performance of Sinopharm Accord’s significant associates declined, and the investment income recognized from associates decreased accordingly.

Sinopharm Accord will deeply grasp the guidance of industry policies and the new trend of medical reform, adhere to strategic guidance, dynamically optimize operation strategies and development paths, focus on the key direction of “open up new sources, reduce expenditure and enhance efficiency”, accelerate digital transformation, deepen organizational transformation and refined management, promote the quality and efficiency improvement and structural optimization of core business, and endeavor to improve the quality of operation.

Shareholders and public investors should note that the principal unaudited financial data and indicators of Sinopharm Accord during the Reporting Period contained in this announcement are only preliminary accounting data, which have not been audited by an accounting firm, and the final data to be disclosed in the interim report of Sinopharm Accord may differ.

By order of the Board
Sinopharm Group Co. Ltd.
Zhao Bingxiang
Chairman

Shanghai, the PRC
14 August 2025

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Sun Jinglin; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.